20 recruiting, 14 active not recruiting, 12 completed, 6 terminated. 39 Phase 3, 23 Phase 2, 3 Not applicable, 1 Phase 1.
By phase and status
Phase Trials Status Phase 3 39 Recruiting 13 , Active not recruiting 10 , Completed 8 , Terminated 3 , Not yet recruiting 2 , Unknown 2 , Withdrawn 1 Phase 2 23 Recruiting 7 , Active not recruiting 4 , Completed 4 , Terminated 4 , Unknown 2 , Not yet recruiting 1 , Withdrawn 1 Not applicable 3 Unknown 2 , Recruiting 1 Phase 1 1 Terminated 1
Follow GOG Foundation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva Tisotumab Vedotin - Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer Phase 2 Not yet recruiting GOG Foundation 28 2026-11-01 2026-06-29 Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer PF-08634404, Pembrolizumab, Standard of Care Chemotherapy - Endometrial Neoplasms, Endometrial Cancer Phase 3 Not yet recruiting Pfizer 600 2026-10-09 2026-10-08 Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers BG-C9074, Bevacizumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer Phase 3 Not yet recruiting BeOne Medicines 600 2026-10-01 2026-09-10 Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Torvutatug samrotecan, Bevacizumab - Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer Phase 3 Recruiting AstraZeneca 600 2026-09-24 2026-10-16 Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer Torvutatug samrotecan, Bevacizumab - Epithelial Ovarian Cancer Phase 3 Recruiting AstraZeneca 950 2026-09-16 2026-10-01 A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression Investigator's choice of Chemotherapy, Azenosertib - Ovarian Cancer Phase 3 Recruiting K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc 420 2026-04-17 2026-08-12 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) Pembrolizumab, Sacituzumab Tirumotecan, Bevacizumab - Cervical Cancer Phase 3 Recruiting Merck Sharp & Dohme LLC 1023 2026-01-19 2026-10-13 AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer AZD5335, Mirvetuximab Soravtansine (MIRV), Paclitaxel - Epithelial Ovarian Cancer Phase 3 Recruiting AstraZeneca 1100 2025-12-29 2026-07-21 Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression INCB123667, Investigator's choice of chemotherapy - Ovarian Cancer Phase 3 Recruiting Incyte Corporation 466 2025-12-09 2026-10-15 A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. Carboplatin, Mirvetuximab Soravtansine, Bevacizumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer Phase 2 Recruiting AbbVie 140 2025-11-21 2026-10-20 A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression INCB123667 - Ovarian Cancer Phase 2 Recruiting Incyte Corporation 160 2025-11-12 2026-09-15 A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer Sofetabart Mipitecan, Paclitaxel, Topotecan - Ovarian Neoplasms, Fallopian Tube Neoplasms Phase 3 Recruiting Eli Lilly and Company 1630 2025-10-22 2026-10-08 A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies IMGN151, Carboplatin, Bevacizumab - Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer Phase 2 Recruiting AbbVie 377 2025-07-30 2026-10-01 A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist - Ovarian Cancer, Fallopian Tube Cancer Phase 3 Recruiting Merck Sharp & Dohme LLC 770 2025-04-09 2026-10-13 DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab - Endometrial Cancer Phase 3 Recruiting AstraZeneca 600 2025-03-27 2026-10-13 Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer Sapanisertib, Serabelisib, Paclitaxel - Endometrial Cancer Phase 2 Recruiting Faeth Therapeutics 40 2024-12-12 2025-12-24 A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer Alpelisib Pill, Fulvestrant injection - Endometroid Endometrial Cancer Phase 2 Active not recruiting GOG Foundation 51 2024-09-11 2026-07-30 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) Sacituzumab govitecan-hziy, Doxorubicin, Paclitaxel - Endometrial Cancer Phase 3 Active not recruiting Gilead Sciences 640 2024-08-28 2026-10-22 A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) Sacituzumab Tirumotecan, Pemetrexed, Tisotumab Vedotin - Cervical Cancer Phase 3 Active not recruiting Merck Sharp & Dohme LLC 686 2024-07-24 2026-08-28 Letrozole in Uterine Leiomyosarcoma Letrozole - Uterine Leiomyosarcoma Phase 2 Recruiting GOG Foundation 40 2024-07-17 2026-07-30
Showing 20 of 63. Sign in to see all of them.
Conditions studied Ovarian Neoplasms (23) · Fallopian Tube Neoplasms (18) · Endometrial Neoplasms (13) · Uterine Cervical Neoplasms (9) · Carcinoma, Ovarian Epithelial (7) · Recurrence (5) · Neoplasm Metastasis (4) · Neoplasms (4) · Parkinson Disease 4, Autosomal Dominant Lewy Body (4) · Brenner Tumor (2) · Genital Diseases (2) · Peritoneal Neoplasms (2) · Uterine Neoplasms (2) · Carcinoma, Endometrioid (1) · Carcinoma, Squamous Cell (1)
Interventions Paclitaxel (24) · Bevacizumab (15) · Carboplatin (14) · Cisplatin (10) · pembrolizumab (7) · Taxes (6) · liposomal doxorubicin (6) · 1,2-diaminocyclohexaneplatinum II citrate (5) · Gemcitabine (5) · Letrozole (5) · Platinum (5) · Topotecan (5) · olaparib (5) · Brachytherapy (3) · Docetaxel (3)
Countries United States (60) · Canada (35) · Spain (32) · South Korea (30) · Italy (29) · Japan (27) · Australia (24) · Belgium (24) · Germany (24) · France (22) · United Kingdom (22) · Israel (20) · Poland (20) · Brazil (19) · China (18)
Top investigators Brian Slomovitz, MD (2) · Rachel Grisham, MD (2) · Allan L Covens (1) · Bradley Corr, MD (1) · Bradley J Monk (1) · Bradley Monk, MD (1) · Carol Aghajanian (1) · David S Miller (1)
Results publications PMID 37185961 , PMID 37650664 , PMID 38431043 , PMID 40644648 , PMID 40966692 , PMID 11224527 , PMID 15240681 , PMID 16382236 , PMID 18586928 , PMID 19097774 , PMID 20516428 , PMID 21074063 , PMID 21525385 , PMID 23728179 , PMID 23897982 , PMID 25539810 , PMID 25619164 , PMID 25922725 , PMID 26398076 , PMID 26403783 , PMID 26558876 , PMID 26858122 , PMID 27141885 , PMID 27269741 , PMID 27717298 , PMID 27932067 , PMID 28040721 , PMID 28228726 , PMID 28607581 , PMID 28636851 , PMID 28678668 , PMID 28835386 , PMID 29423118 , PMID 29617360 , PMID 29657128 , PMID 29731394 , PMID 30309721 , PMID 30345884 , PMID 30630885 , PMID 31912685 , PMID 32460997 , PMID 33078978 , PMID 33637348 , PMID 33862001 , PMID 33891472 , PMID 34201380 , PMID 34409858 , PMID 34686353 , PMID 34715071 , PMID 35007153
NIH funding U10CA180868 (10), U10CA027469 (9), 2023 (6), 2025 (4), 2017 (3), 2019 (2), U10CA101165 (2), UG1CA189867 (2), 2016 (1), N01CM62201 (1)